Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial

BACKGROUND: Myeloma causes profound immunodeficiency and recurrent, serious infections. Around 5500 new cases of myeloma are diagnosed per year in the UK, and a quarter of patients will have a serious infection within 3 months of diagnosis. We aimed to assess whether patients newly diagnosed with my...

Descripción completa

Detalles Bibliográficos
Autores principales: Drayson, Mark T, Bowcock, Stella, Planche, Tim, Iqbal, Gulnaz, Pratt, Guy, Yong, Kwee, Wood, Jill, Raynes, Kerry, Higgins, Helen, Dawkins, Bryony, Meads, David, Hulme, Claire T, Monahan, Irene, Karunanithi, Kamaraj, Dignum, Helen, Belsham, Edward, Neilson, Jeff, Harrison, Beth, Lokare, Anand, Campbell, Gavin, Hamblin, Michael, Hawkey, Peter, Whittaker, Anna C, Low, Eric, Dunn, Janet A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891230/
https://www.ncbi.nlm.nih.gov/pubmed/31668592
http://dx.doi.org/10.1016/S1470-2045(19)30506-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891230/
https://www.ncbi.nlm.nih.gov/pubmed/31668592
http://dx.doi.org/10.1016/S1470-2045(19)30506-6

Ejemplares similares